After finishing at $10.25 in the prior trading day, Mind Medicine Inc (NASDAQ: MNMD) closed at $9.67, down -5.66%. On the day, 1371661 shares were traded.
Ratios:
Our goal is to gain a better understanding of MNMD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.22 and its Current Ratio is at 3.22. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on December 05, 2023, initiated with a Buy rating and assigned the stock a target price of $9.
On November 16, 2022, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $5.RBC Capital Mkts initiated its Outperform rating on November 16, 2022, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’24 when Barrow Robert sold 16,519 shares for $9.50 per share. The transaction valued at 156,930 led to the insider holds 580,202 shares of the business.
Karlin Dan sold 6,578 shares of MNMD for $62,491 on Mar 25 ’24. The Chief Medical Officer now owns 358,452 shares after completing the transaction at $9.50 per share. On Dec 26 ’23, another insider, Barrow Robert, who serves as the Chief Executive Officer of the company, sold 13,237 shares for $3.63 each. As a result, the insider received 48,050 and left with 596,721 shares of the company.
Stock Price History:
Over the past 52 weeks, MNMD has reached a high of $12.22, while it has fallen to a 52-week low of $2.41.
Shares Statistics:
A total of 41.10M shares are outstanding, with a floating share count of 26.94M. Insiders hold about 4.34% of the company’s shares, while institutions hold 61.39% stake in the company.
Earnings Estimates
Its stock is currently analyzed by MannKind Corporation different market analysts. The consensus estimate for the next quarter is $17.92, with high estimates of $29.02 and low estimates of $9.67.
